HK40062425A - Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration - Google Patents

Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration Download PDF

Info

Publication number
HK40062425A
HK40062425A HK62022052031.1A HK62022052031A HK40062425A HK 40062425 A HK40062425 A HK 40062425A HK 62022052031 A HK62022052031 A HK 62022052031A HK 40062425 A HK40062425 A HK 40062425A
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical formulations
subcutaneous administration
inhibitors suitable
fcrn inhibitors
fcrn
Prior art date
Application number
HK62022052031.1A
Other languages
Chinese (zh)
Inventor
Filip BORGIONS
Stephanie Lemoult
Kris Meerschaert
Original Assignee
Argenx Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenx Bvba filed Critical Argenx Bvba
Publication of HK40062425A publication Critical patent/HK40062425A/en

Links

HK62022052031.1A 2019-06-07 2020-06-05 Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration HK40062425A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62/858,806 2019-06-07

Publications (1)

Publication Number Publication Date
HK40062425A true HK40062425A (en) 2022-06-10

Family

ID=

Similar Documents

Publication Publication Date Title
IL288550A (en) Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration
IL275639A (en) Formulation for administration of rna
EP3881827B8 (en) Formulation for administration of rna
AU2018297348A1 (en) Compositions for parenteral administration of therapeutic agents
EP3773730A4 (en) Drug delivery formulations
WO2019240699A3 (en) Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion
EP4027973B8 (en) Drug delivery formulations
EP3952924A4 (en) Compositions and methods for administration of therapeutics
EP4004017A4 (en) Platelet-facilitated delivery of therapeutic compounds
EP4114396A4 (en) Methods of administering elagolix
EP4085911A4 (en) Pharmaceutical composition for oral administration, for treatment of liver cancer
SG11202104499RA (en) Pharmaceutical formulations for subcutaneous administration
HK40062425A (en) Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration
EP4326265A4 (en) Pharmaceutical hydronidone formulations for diseases
EP3515438A4 (en) Drug delivery system for the delivery of integrase inhibitors
EP3982937A4 (en) Pharmaceutical formulations containing gaboxadol for therapeutic treatment
EP4048678A4 (en) Compounds and compositions for the treatment of parasitic diseases
HK40041225A (en) Formulation for administration of rna
HK40075060A (en) Pharmaceutical formulations of tenofovir alafenamide
HK40082107A (en) Formulations of anti-cd38 antibodies for subcutaneous administration
HK40073247A (en) Pharmaceutical composition of darolutamide
HK40051042A (en) Compositions for drug delivery and methods of use thereof
HK40052480A (en) Pharmaceutical formulation of odevixibat
HK40042140A (en) Drug formulation for dermal diseases
HK40078214A (en) Pharmaceutical compounds and methods of use